Unusual 11 Mid-Day Movers 11/27: (ACAD) (IMMR) (PPHM) Higher; (NEPT) (MMR) (STV) Lower
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) 137.4% HIGHER; reported that pimavanserin met the primary endpoint in the Phase III trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale (p=0.001).
Immersion Corp (Nasdaq: IMMR) 30.2% HIGHER; shares are ripping higher Tuesday following a release earlier stating that it entered into a settlement and license agreement with Google, Inc. (Nasdaq: GOOG) and Motorola Mobility LLC, resolving the patent infringement litigation brought by Immersion against Motorola. Shares are up over 23 percent early.
Neptune Technologies (Nasdaq: NEPT) 29.3% LOWER; lower as shares were halted for the better part of November following an explosion at its Quebec plan. The company also announced that on November 9, 2012 it filed a Notice of Opposition in Australia against Aker Biomarine ASA's patent application no. AU2008291978 entitled "New Method for Making Krill Meal".
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) 26.8% HIGHER; energized as the pharma sector receives some positive attention from Acadia today.
Ralcorp Holdings Inc. (NYSE: RAH) 26.5% HIGHER; ConAgra (NYSE: CAG) will acquire Ralcorp for $90 per share.
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) 14.0% HIGHER; reports that Purdue Pharmaceutical Products, L.P. (Purdue), the Transcept U.S. commercialization partner for Intermezzo (zolpidem tartrate) sublingual tablet C-IV, is launching a national direct-to-consumer (DTC) promotional campaign, including digital, print and television advertising to support Intermezzo commercialization.
Zalicus Inc. (Nasdaq: ZLCS) 13.6% HIGHER; announced that Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker in Phase 2 clinical development for chronic neuropathic pain, has been chosen by Windhover as one of the Top 10 Neuroscience Projects to Watch. Mark Corrigan, MD, CEO of Zalicus, will provide a summary of Z160 during his presentation at the Windhover 2012 Therapeutic Area Partnership meeting being held at the Westin Copley Place Boston at 1:30 p.m. ET on Thursday, November 29, 2012 during the Top 10 Neuroscience Projects to Watch session.
McMoRan Exploration (NYSE: MMR) 13.6% LOWER; lower as RBC Capital downgraded the stock to Sector Perform and JPMorgan issued negative comments as well.
China Digital TV Holding (NYSE: STV) 11.5% LOWER; continuing to see pressure following Q3 results released last week.
Thor Industries, Inc. (NYSE: THO) 11.5% LOWER; reported Q1 EPS of $0.59, $0.03 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $875.6 million versus the consensus estimate of $876.8 million.
China BAK Battery, Inc. (Nasdaq: CBAK) 9.5% LOWER; recoiling a little after ripping 54 percent Monday on stronger volume.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Immersion Corp (Nasdaq: IMMR) 30.2% HIGHER; shares are ripping higher Tuesday following a release earlier stating that it entered into a settlement and license agreement with Google, Inc. (Nasdaq: GOOG) and Motorola Mobility LLC, resolving the patent infringement litigation brought by Immersion against Motorola. Shares are up over 23 percent early.
Neptune Technologies (Nasdaq: NEPT) 29.3% LOWER; lower as shares were halted for the better part of November following an explosion at its Quebec plan. The company also announced that on November 9, 2012 it filed a Notice of Opposition in Australia against Aker Biomarine ASA's patent application no. AU2008291978 entitled "New Method for Making Krill Meal".
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) 26.8% HIGHER; energized as the pharma sector receives some positive attention from Acadia today.
Ralcorp Holdings Inc. (NYSE: RAH) 26.5% HIGHER; ConAgra (NYSE: CAG) will acquire Ralcorp for $90 per share.
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) 14.0% HIGHER; reports that Purdue Pharmaceutical Products, L.P. (Purdue), the Transcept U.S. commercialization partner for Intermezzo (zolpidem tartrate) sublingual tablet C-IV, is launching a national direct-to-consumer (DTC) promotional campaign, including digital, print and television advertising to support Intermezzo commercialization.
Zalicus Inc. (Nasdaq: ZLCS) 13.6% HIGHER; announced that Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker in Phase 2 clinical development for chronic neuropathic pain, has been chosen by Windhover as one of the Top 10 Neuroscience Projects to Watch. Mark Corrigan, MD, CEO of Zalicus, will provide a summary of Z160 during his presentation at the Windhover 2012 Therapeutic Area Partnership meeting being held at the Westin Copley Place Boston at 1:30 p.m. ET on Thursday, November 29, 2012 during the Top 10 Neuroscience Projects to Watch session.
McMoRan Exploration (NYSE: MMR) 13.6% LOWER; lower as RBC Capital downgraded the stock to Sector Perform and JPMorgan issued negative comments as well.
China Digital TV Holding (NYSE: STV) 11.5% LOWER; continuing to see pressure following Q3 results released last week.
Thor Industries, Inc. (NYSE: THO) 11.5% LOWER; reported Q1 EPS of $0.59, $0.03 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $875.6 million versus the consensus estimate of $876.8 million.
China BAK Battery, Inc. (Nasdaq: CBAK) 9.5% LOWER; recoiling a little after ripping 54 percent Monday on stronger volume.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- After-Hours Movers: AMAT, DLO, GLOB, YSS, ETON
Create E-mail Alert Related Categories
Special ReportsRelated Entities
JPMorgan, RBC Capital, Unusual 11 Mid-Day Movers, Motorola Mobility/GoogleSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
